The Interferons: Characterization and Application

At long last, the first book to cover all important areas of interferon science in one volume. Top scientists, including many pioneers in the field, highlight the role of interferons as research tools and as therapeutic agents in clinical applications. Edited by an experienced interferonologist, chapters include discussions of interferon genes, Type I, II and III IFNs, as well as their induction, production and purification, receptors actions, measuring IFN activities and anti-IFN antibodies, as well as the evolution of viral defense mechanisms.
For immunologists, cancer researchers, medicinal chemists, cell biologists, developmental biologists and the pharmaceutical industry.

At long last, the first book to cover all important areas of interferon science in one volume. Top scientists, including many pioneers in the field, highlight the role of interferons as research tools and as therapeutic agents in clinical applications. Edited by an experienced interferonologist, chapters include discussions of interferon genes, Type I, II and III IFNs, as well as their induction, production and purification, receptors actions, measuring IFN activities and anti-IFN antibodies, as well as the evolution of viral defense mechanisms.

For immunologists, cancer researchers, medicinal chemists, cell biologists, developmental biologists and the pharmaceutical industry.

Anthony Meager is a Principal Scientist in the Division of Immunology and Endocrinology, The National Institute for Biological Standards and Control (NIBSC), UK. Following his PhD in Biochemistry (Warwick University, UK, 1972), he has carried out research in biochemistry, cell biology, immunology, virology, and cytokines, especially interferons (IFN) and tumor necrosis factor (TNF). He joined the NIBSC in 1980. Currently, he heads laboratories involved in the biological standardization of IFN and TNF, and research studies on the bioactivity and immunogenicity of cytokines. From 1990, he has also contributed to regulatory guidance on gene therapy, both for the European Medicines Agency and the World Health Organization.